StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross jointly filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,407,181 common shares of Edesa Biotech, Inc. as of September 30, 2026.

Key Highlights

  • Three reporting persons: StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross filed jointly as a group.
  • Aggregate beneficial ownership: Each reporting person is reported as beneficially owning 1,407,181 common shares, without par value.
  • Percent of class: The 1,407,181 shares represent 9.9% of Edesa Biotech's common shares, as stated in the filing.
  • Pre-funded warrants included: The total includes 825,000 common shares and 582,181 shares obtainable through exercise of pre-funded warrants, subject to a 9.99% beneficial ownership limitation.
  • Excluded shares: 242,819 shares underlying the pre-funded warrants are excluded from the reported total due to the beneficial ownership limitation.
  • Shares outstanding basis: The percentage is calculated using 13,503,723 common shares believed outstanding, as disclosed in the issuer's Prospectus Supplement on Form 424B5 filed August 20, 2026, plus the 582,181 warrant shares.
  • Voting and dispositive power: All 1,407,181 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each zero.

StemPoint Capital and Michelle Ross Report Combined 9.9% Position in Edesa Biotech

According to the Schedule 13G filed November 16, 2026, StemPoint Capital LP, its general partner StemPoint Capital Management GP LLC, and Michelle Ross jointly disclosed a beneficial ownership position in Edesa Biotech, Inc. (NASDAQ:EDSA). The event triggering the filing occurred on September 30, 2026. The filing identifies StemPoint Capital LP as organized under the laws of Delaware, StemPoint Capital Management GP LLC as a Delaware limited liability company, and Michelle Ross as a citizen of the United States, all with a shared business address at 520 Madison Avenue, 19th Floor, New York, NY 10022.

The filing states that the 1,407,181 shares beneficially owned by each reporting person consist of two components: 825,000 shares of common shares held directly, and 582,181 shares of common shares obtainable through the exercise of pre-funded warrants. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99%, according to the filing. As a result, an additional 242,819 shares underlying the pre-funded warrants are excluded from the reported beneficial ownership total. The filing notes that the percentage in Row 11 of each cover page has been rounded down to 9.9% due to field limitations of the EDGAR filing system.

The filing certifies, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." StemPoint Capital LP is classified as an investment adviser and limited partnership, StemPoint Capital Management GP LLC as a limited liability company, and Michelle Ross as a holding company and individual, per the type-of-reporting-person designations in the filing. The filing was signed by Sean C. Tan as authorized signatory for both StemPoint entities, and by Michelle Ross personally, each dated November 16, 2026.

What Was Disclosed

Three affiliated reporting persons jointly disclosed beneficial ownership of 1,407,181 common shares of Edesa Biotech, representing 9.9% of the class as of September 30, 2026. The position includes direct shares and shares tied to pre-funded warrants subject to a 9.99% ownership cap.